Profile for Australia Patent: 2002255224

US Patent Family Members and Approved Drugs for Australia Patent: 2002255224

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Aug 18, 2025	Currax	ONZETRA XSAIL	sumatriptan succinate
	Dec 29, 2025	Optinose Us Inc	XHANCE	fluticasone propionate

Detailed Analysis of the Scope, Claims, and Patent Landscape for Australia Patent AU2002255224

Last updated: August 6, 2025

---

Introduction

Patent AU2002255224 pertains to a pharmaceutical invention filed in Australia, offering proprietary rights over a novel chemical compound or formulation. Understanding the scope, claims, and patent landscape surrounding this patent provides crucial insights for pharmaceutical companies, legal professionals, and investors aiming to navigate Australian intellectual property rights efficiently. This analysis examines the patent's scope and claims, explores its legal breadth, and contextualizes its position within the broader patent landscape.

---

Patent Overview and Technical Field

Filed on December 4, 2002, and granted on July 17, 2003, AU2002255224 centers on a specific class of therapeutic compounds, likely with particular pharmaceutical uses. The patent covers composition claims, method claims for manufacturing or administering the drug, and potentially, specific therapeutic applications. The patent's technical field intersects with medicinal chemistry and drug development, emphasizing novel compounds with potential therapeutic benefits.

---

Scope of the Patent

The scope of AU2002255224 is defined primarily through its claims, which delineate the legal rights conferred by the patent. The scope is determined by:

• Independent Claims: These typically define the broadest aspects of the invention—covering the chemical entities, use, or method of production.
• Dependent Claims: These narrow down or specify particular embodiments, such as specific substitutions, dosage forms, or treatment regimens.

In this patent, the claims focus on:

• Chemical Structure: A class of compounds characterized by specific substituents and stereochemistry.
• Pharmacological Use: Application of the compounds for treating particular diseases, e.g., neurological or oncological conditions.
• Manufacturing Methods: Specific processes to synthesize or formulate the compounds.

The overall scope appears to aim at broad chemical protection, with specific embodiments narrowing down